Close

Bristol-Myers Squibb (BMY) Announces FDA Expanded Approval for Sprycel to Include Children with Ph+ CML in Chronic Phase

November 10, 2017 6:31 AM EST Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel® ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login